For frail elderly patients, it's crucial to discern if poor performance status stems from disease or comorbidities. A practical approach is to initiate treatment with biologic agents alone. If the patient's status improves, it confirms the cancer is the cause, justifying the subsequent, careful addition of cytotoxic chemotherapy.

An expert argues the path to curing metastatic cancer may mirror pediatric ALL's history: combining all highly active drugs upfront. Instead of sequencing treatments after failure, the focus should be on powerful initial regimens that eradicate cancer, even if it means higher initial toxicity.

For frail elderly patients with HER2+ gastric cancer, starting with targeted therapy and immunotherapy alone can gauge response and tolerance. Cytotoxic chemotherapy can be added later if the patient's performance status improves, distinguishing disease-related frailty from baseline comorbidities.

New targeted therapies like Zanidatamab and Zolbetuximab show great promise but cause significant side effects like diarrhea and nausea. Their successful clinical adoption hinges on proactive management using detailed guidelines and prophylactic medications, as toxicity can be severe enough to force treatment discontinuation despite the drug's efficacy.

In the increasingly common scenario of gastric cancer with multiple biomarkers (HER2, PD-L1, Claudin), experts recommend a clear hierarchy. Based on data maturity, HER2-targeted therapy is the first choice, followed by PD-L1 immunotherapy, with Claudin-targeted therapy third.

Contrary to concerns about over-complicating treatment, experts advocate for fragmenting gastric cancer even further. The goal is to treat each molecularly defined subset as its own distinct disease, which requires deeper understanding and more targeted approaches rather than broad simplification.

For acutely ill patients with strong clinical suspicion of SCLC, delaying treatment for biopsy confirmation can mean losing the window for effective intervention. Initiating chemotherapy in the hospital based on clinical presentation is a critical, potentially life-saving measure.

For patients with very high-burden or symptomatic mesothelioma, clinicians may deviate from standard guidelines. They may choose chemo-immunotherapy to maximize the chance of a rapid response, viewing it as their single best opportunity to control the disease, especially if the patient's condition is precarious.

Clinicians advise against continuing targeted agents like zolbituximab or trastuzumab after disease progression in gastroesophageal cancer. The biological heterogeneity of this cancer type means that if a targeted therapy isn't working, it's unlikely to provide benefit with a different chemotherapy backbone.